PolyMPC-doxorubicin prodrugs

Bioconjugate Chemistry

Volumn 23, Issue 9, 2012, Pages 1753-1763

  Chen, Xiangji ^a   Parelkar, Sangram S ^a   Henchey, Elizabeth ^b   Schneider, Sallie ^b   Emrick, Todd ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b Pioneer Valley Life Sciences Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED DRUG DELIVERY; DRUG DOSAGE; POLYMERIZATION; TARGETED DRUG DELIVERY;

CANCER DRUG; DOXORUBICIN; DOXORUBICIN CONJUGATES; HYDRAZONES; METHACRYLOYLOXYETHYL PHOSPHORYLCHOLINE; ONE POT; ONE-POT METHOD; POST-POLYMERIZATION; PRODRUGS; SINGLE-STEP;

CELL CULTURE;

2 METHACRYLOYLOXYETHYLPHOSPHORYLCHOLINE; DOXORUBICIN; HYDRAZONE DERIVATIVE; POLY(METHACRYLOYLOXYETHYL PHOSPHORYLCHOLINE); PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG HALF LIFE; DRUG RELEASE; HUMAN; HUMAN CELL; IC 50; MAXIMUM TOLERATED DOSE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; ONE POT SYNTHESIS; PH; POLYMERIZATION;

MUS;

EID: 84866356894     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc200667s     Document Type: Article

References (57)

1. Davis, M. E., Chen, Z., and Shin, D. M. (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Drug Discovery 7, 771-782
2. Petros, R. A. and DeSimone, J. M. (2010) Strategies in the design of nanoparticles for therapeutic applications Nat. Rev. Drug Discovery 9, 615-627
3. Vicent, M. J. and Duncan, R. (2006) Polymer conjugates: nanosized medicines for treating cancer Trends Biotechnol. 24, 39-47 (Pubitemid 43017749)
4. Duncan, R. (2006) Polymer conjugates as anticancer nanomedicines Nat. Rev. Cancer 6, 688-701 (Pubitemid 44286001)
5. Greco, F. and Vicent, M. J. (2009) Combination therapy: Opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines Adv. Drug Delivery Rev. 61, 1203-1213
6. Haag, R. and Kratz, F. (2006) Polymer therapeutics: Concepts and applications Angew. Chem., Int. Ed. 45, 1198-1215 (Pubitemid 44097641)
7. Pasut, G. and Veronese, F. M. (2009) PEG conjugates in clinical development or use as anticancer agents: An overview Adv. Drug Delivery Rev. 61, 1177-1188
8. Matsumura, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer-chemotherapy-mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46, 6387-6392 (Pubitemid 17221789)
9. Maeda, H. and Matsumura, Y. (1989) Tumoritropic and lymphotropic principles of macromolecular drugs Crit. Rev. Ther. Drug Carr. Syst. 6, 193-210 (Pubitemid 20065994)
10. Maeda, H., Sawa, T., and Konno, T. (2001) Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS J. Controlled Release 74, 47-61 (Pubitemid 32727608)
11. Ringsdorf, H. (1975) Structure and properties of pharmacologically active polymers J. Polym. Sci., Part C: Polym. Symp. 135-153
12. Greenwald, R. B., Choe, Y. H., McGuire, J., and Conover, C. D. (2003) Effective drug delivery by PEGylated drug conjugates Adv. Drug Delivery Rev. 55, 217-250 (Pubitemid 36135917)
13. Thomson, A. H., Vasey, P. A., Murray, L. S., Cassidy, J., Fraier, D., Frigerio, E., and Twelves, C. (1999) Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours Br. J. Cancer 81, 99-107 (Pubitemid 29415498)
14. Seymour, L. W., Ferry, D. R., Kerr, D. J., Rea, D., Whitlock, M., Poyner, R., Boivin, C., Hesslewood, S., Twelves, C., Blackie, R., Schatzlein, A., Jodrell, D., Bissett, D., Calvert, H., Lind, M., Robbins, A., Burtles, S., Duncan, R., and Cassidy, J. (2009) Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer Int. J. Oncol. 34, 1629-1636
15. Bissett, D., Cassidy, J., de Bono, J. S., Muirhead, F., Main, M., Robson, L., Fraier, D., Magne, M. L., Pellizzoni, C., Porro, M. G., Spinelli, R., Speed, W., and Twelves, C. (2004) Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT) Br. J. Cancer 91, 50-55 (Pubitemid 39013044)
16. Li, C., Yu, D. F., Newman, R. A., Cabral, F., Stephens, L. C., Hunter, N., Milas, L., and Wallace, S. (1998) Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid) paclitaxel conjugate Cancer Res. 58, 2404-2409 (Pubitemid 28252701)
17. Bhatt, R. L., de Vries, P., Tulinsky, J., Bellamy, G., Baker, B., Singer, J. W., and Klein, P. (2003) Synthesis and in vivo antitumor activity of poly(L-glutamic acid) conjugates of 20(S)-camptothecin J. Med. Chem. 46, 190-193 (Pubitemid 36043799)
18. Schluep, T., Hwang, J., Cheng, J. J., Heidel, J. D., Bartlett, D. W., Hollister, B., and Davis, M. E. (2006) Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models Clin. Cancer Res. 12, 1606-1614
19. Numbenjapon, T., Wang, J. Y., Colcher, D., Schluep, T., Davis, M. E., Duringer, J., Kretzner, L., Yen, Y., Forman, S. J., and Raubitschek, A. (2009) Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models Clin. Cancer Res. 15, 4365-4373
20. Soepenberg, O., de Jonge, M. J. A., Sparreboom, A., de Bruin, P., Eskens, F., de Heus, G., Wanders, J., Cheverton, P., Ducharme, M. P., and Verweij, J. (2005) Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors Clin. Cancer Res. 11, 703-711 (Pubitemid 40116898)
21. Yurkovetskiy, A. V. and Fram, R. J. (2009) XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer Adv. Drug Delivery Rev. 61, 1193-1202
22. Lewis, A. L. (2000) Phosphorylcholine-based polymers and their use in the prevention of biofouling Colloid Surf., B: Biointerfaces 18, 261-275 (Pubitemid 30479867)
23. Ishihara, K. and Iwasaki, Y. (1998) Reduced protein adsorption on novel phospholipid polymers J. Biomater. Appl. 13, 111-127 (Pubitemid 128615742)
24. Ishihara, K., Nomura, H., Mihara, T., Kurita, K., Iwasaki, Y., and Nakabayashi, N. (1998) Why do phospholipid polymers reduce protein adsorption? J. Biomed. Mater. Res. 39, 323-330 (Pubitemid 28060367)
25. Ishihara, K. (2000) New polymeric biomaterials: Phospholipid polymers with a biocompatible surface Front. Med. Biol. Eng. 10, 83-95
26. Iwasaki, Y. and Ishihara, K. (2005) Phosphorylcholine-containing polymers for biomedical applications Anal. Bioanal. Chem. 381, 534-546 (Pubitemid 40379326)
27. Ishihara, K. and Takai, M. (2009) Bioinspired interface for nanobiodevices based on phospholipid polymer chemistry J. R. Soc. Interface 6, S279-S291
28. Lewis, A. L., Hughes, P. D., Kirkwood, L. C., Leppard, S. W., Redman, R. P., Tolhurst, L. A., and Stratford, P. W. (2000) Synthesis and characterisation of phosphorylcholine-based polymers useful for coating blood filtration devices Biomaterials 21, 1847-1859 (Pubitemid 30398503)
29. Samanta, D., McRae, S., Cooper, B., Hu, Y. X., and Emrick, T. (2008) End-functionalized phosphorylcholine methacrylates and their use in protein conjugation Biomacromolecules 9, 2891-2897
30. Lewis, A., Tang, Y. Q., Brocchini, S., Choi, J. W., and Godwin, A. (2008) Poly(2-methacryloyloxyethyl phosphorylcholine) for protein conjugation Bioconjugate Chem. 19, 2144-2155
31. Chen, X. J., McRae, S., Parelkar, S., and Emrick, T. (2009) Polymeric phosphorylcholine-camptothecin conjugates prepared by controlled free radical polymerization and click chemistry Bioconjugate Chem. 20, 2331-2341
32. Berry, G., Billingham, M., Alderman, E., Richardson, P., Torti, F., Lum, B., Patek, A., and Martin, F. J. (1998) The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposis sarcoma patients treated with pegylated liposomal doxorubicin Ann. Oncol. 9, 711-716 (Pubitemid 28394155)
33. Safra, T., Muggia, F., Jeffers, S., Tsao-Wei, D. D., Groshen, S., Lyass, O., Henderson, R., Berry, G., and Gabizon, A. (2000) Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m(2) Ann. Oncol. 11, 1029-1033
34. Lotem, M., Hubert, A., Lyass, O., Goldenhersh, M. A., Ingber, A., Peretz, T., and Gabizon, A. (2000) Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin Arch. Dermatol. 136, 1475-1480 (Pubitemid 32009267)
35. Hamilton, A., Biganzoli, L., Coleman, R., Mauriac, L., Hennebert, P., Awada, A., Nooij, M., Beex, L., Piccart, M., Van Hoorebeeck, I., Bruning, P., and de Valeriola, D. (2002) EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx (R), Doxil (R)) at a 6-week interval in patients with metastatic breast cancer Ann. Oncol. 13, 910-918 (Pubitemid 34752687)
36. Uziely, B., Jeffers, S., Isacson, R., Kutsch, K., Weitsao, D., Yehoshua, Z., Libson, E., Muggia, F. M., and Gabizon, A. (1995) Liposomal doxorubicin-antitumor-activity and unique toxicities during 2 complementary phase-I studies J. Clin. Oncol. 13, 1777-1785
37. Elbayoumi, T. A. and Torchilin, V. P. (2008) Tumor-specific antibody-mediated targeted delivery of Doxil (R) reduces the manifestation of auricular erythema side effect in mice Int. J. Pharm. 357, 272-279
38. Coley, H. M., Twentyman, P. R., and Workman, P. (1993) The efflux of anthracyclines in multidrug-resistant cell-lines Biochem. Pharmacol. 46, 1317-1326
39. Harris, A. L. and Hochhauser, D. (1992) Mechanisms of multidrug resistance in cancer-treatment Acta Oncol. 31, 205-213
40. Minko, T., Kopeckova, P., Pozharov, V., and Kopecek, J. (1998) HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line J. Controlled Release 54, 223-233 (Pubitemid 28342701)
41. Minko, T., Paranjpe, P. V., Qiu, B., Lalloo, A., Won, R., Stein, S., and Sinko, P. J. (2002) Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethyleneglycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells Cancer Chemother. Pharmacol. 50, 143-150 (Pubitemid 34969511)
42. Lee, C. C., Gillies, E. R., Fox, M. E., Guillaudeu, S. J., Frechet, J. M. J., Dy, E. E., and Szoka, F. C. (2006) A single dose of doxorubicin- functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas Proc. Natl. Acad. Sci. U. S. A. 103, 16649-16654 (Pubitemid 44737307)
43. Etrych, T., Jelinkova, M., Rihova, B., and Ulbrich, K. (2001) New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties J. Controlled Release 73, 89-102 (Pubitemid 32406104)
44. Ulbrich, K., Etrych, T., Chytil, P., Jelinkova, M., and Rihova, B. (2003) HPMA copolymers with pH-controlled release of doxorubicin-In vitro cytotoxicity and in vivo antitumor activity J. Controlled Release 87, 33-47 (Pubitemid 36258386)
45. Mrkvan, T., Sirova, M., Etrych, T., Chytil, P., Strohalm, J., Plocova, D., Ulbrich, K., and Rihova, B. (2005) Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity J. Controlled Release 110, 119-129 (Pubitemid 41713936)
46. Vetvicka, D., Hruby, M., Hovorka, O., Etrych, T., Vetrik, M., Kovar, L., Kovar, M., Ulbrich, K., and Rihova, B. (2009) Biological evaluation of polymeric micelles with covalently bound doxorubicin Bioconjugate Chem. 20, 2090-2097
47. van der Poll, D. G., Kieler-Ferguson, H. M., Floyd, W. C., Guillaudeu, S. J., Jerger, K., Szoka, F. C., and Frechet, J. M. (2010) Design, synthesis, and biological evaluation of a robust, biodegradable dendrimer Bioconjugate Chem. 21, 764-773
48. Tannock, I. F. and Rotin, D. (1989) Acid pH in tumors and its potential for therapeutic exploitation Cancer Res. 49, 4373-4384 (Pubitemid 19208329)
49. Engin, K., Leeper, D. B., Cater, J. R., Thistlethwaite, A. J., Tupchong, L., and McFarlane, J. D. (1995) Extracellular pH distribution in human tumors Int. J. Hyperthermia 11, 211-216
50. Mellman, I., Fuchs, R., and Helenius, A. (1986) Acidification of the endocytic and exocytic pathways Annu. Rev. Biochem. 55, 663-700 (Pubitemid 16070784)
51. Curci, M., Mieloszynski, J. L., and Paquer, D. (1993) Synthesis of functionalized acrylates Org. Prep. Proc. Int. 25, 649-657
52. Etrych, T., Chytil, P., Jelinkova, M., Rihova, B., and Ulbrich, K. (2002) Synthesis of HPMA copolymers containing doxorubicin bound via a hydrazone linkage. Effect of spacer on drug release and in vitro cytotoxicity Macromol. Biosci. 2, 43-52 (Pubitemid 44790994)
53. Prabaharan, M., Grailer, J. J., Pilla, S., Steeber, D. A., and Gong, S. Q. (2009) Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery Biomaterials 30, 5757-5766
54. Kwon, G., Naito, M., Yokoyama, M., Okano, T., Sakurai, Y., and Kataoka, K. (1997) Block copolymer micelles for drug delivery: loading and release of doxorubicin J. Controlled Release 48, 195-201 (Pubitemid 27401978)
55. Lee, S. M., Chen, H. M., OHalloran, T. V., and Nguyen, S. T. (2009) Clickable polymer-caged nanobins as a modular drug delivery platform J. Am. Chem. Soc. 131, 9311-9320
56. Ishihara, K., Ueda, T., and Nakabayashi, N. (1990) Preparation of phospholipid polymers and their properties as polymer hydrogel membranes Polym. J. 22, 355-360 (Pubitemid 20719572)
57. Ladmiral, V., Mantovani, G., Clarkson, G. J., Cauet, S., Irwin, J. L., and Haddleton, D. M. (2006) Synthesis of neoglycopolymers by a combination of click chemistry and living radical polymerization J. Am. Chem. Soc. 128, 4823-4830